VEGF-Mediated Cell Survival in Non-Small-Cell Lung Cancer: Implications for Epigenetic Targeting of VEGF Receptors as a Therapeutic Approach

References

• Alberg AJ , FordJG , SametJM . Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition) . Chest132 ( 3 Suppl. ), S29 – S55 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ , EllisLM . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis . J. Clin. Oncol.23 ( 5 ), 1011 – 1027 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Favier B , AlamA , BarronPet al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration . Blood108 ( 4 ), 1243 – 1250 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Soker S , MiaoHQ , NomiM , TakashimaS , KlagsbrunM . VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding . J. Cell. Biochem.85 ( 2 ), 357 – 368 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Pajares MJ , AgorretaJ , LarrayozMet al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung . J. Clin. Oncol.30 ( 10 ), 1129 – 1136 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ding M , LiuL , HuC , LiuY , QiaoY , JiangX . Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance . Chin. J. Cancer Res.26 ( 6 ), 669 – 677 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Lantuejoul S , ConstantinB , DrabkinH , BrambillaC , RocheJ , BrambillaE . Expression of vegf, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines . J. Pathol.200 ( 3 ), 336 – 347 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Pidgeon GP , BarrMP , CathcartMC , GrayS , O’ByrneKJ . Neuropilin-1 expression in adenocarcinoma and squamous cell carcinoma of the lung is differentially regulated by hypoxia . ASCO Meeting Abstracts24 ( 18 Suppl. ), 17152 ( 2006 ).
   Google Scholar
• Barr MP , GraySG , GatelyKet al. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer . Mol. Cancer14 ( 1 ), 45 ( 2015 ).
   PubMedGoogle Scholar
• Easwaran H , TsaiHC , BaylinSB . Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance . Mol. Cell54 ( 5 ), 716 – 727 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ , BarrMP , GraySG . The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer . Cancers (Basel)3 ( 1 ), 1426 – 1453 ( 2011 ).
   PubMedGoogle Scholar
• Philibert RA , SearsRA , PowersLSet al. Coordinated DNA methylation and gene expression changes in smoker alveolar macrophages: specific effects on VEGF receptor 1 expression . J. Leukoc. Biol.92 ( 3 ), 621 – 631 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kim J , HwangJ , JeongHet al. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells . Epigenetics7 ( 2 ), 191 – 200 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Roybal JD , ZangY , AhnYHet al. mir-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting FLT1/VEGFR1 . Mol. Cancer Res.9 ( 1 ), 25 – 35 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Shi L , ZhangS , WuHet al. mir-200c increases the radiosensitivity of non-small-cell lung cancer cell line a549 by targeting VEGF–VEGFR2 pathway . PLoS ONE8 ( 10 ), e78344 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gray SG , EkstromTJ . The human histone deacetylase family . Exp. Cell. Res.262 ( 2 ), 75 – 83 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Deroanne CF , BonjeanK , ServotteSet al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling . Oncogene21 ( 3 ), 427 – 436 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kurschat P , BielenbergD , Rossignol-TallandierM , StahlA , KlagsbrunM . Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration . J. Biol. Chem.281 ( 5 ), 2721 – 2729 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kim MS , KwonHJ , LeeYMet al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes . Nat. Med.7 ( 4 ), 437 – 443 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Brazelle W , KreahlingJM , GemmerJet al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells . PLoS ONE5 ( 12 ), e14335 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gray SG , Al-SarrafN , BairdAM , CathcartMC , McgovernE , O’ByrneKJ . Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications . Eur. J. Cancer45 ( 17 ), 3087 – 3097 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Tang YA , WenWL , ChangJWet al. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer . PLoS ONE5 ( 9 ), e12417 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Patnaik A , LorussoPM , MessersmithWAet al. A Phase Ib study evaluating mnrp1685a, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors . Cancer Chemother. Pharmacol.73 ( 5 ), 951 – 960 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Langevin SM , KratzkeRA , KelseyKT . Epigenetics of lung cancer . Transl. Res.165 ( 1 ), 74 – 90 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Liloglou T , BediagaNG , BrownBR , FieldJK , DaviesMP . Epigenetic biomarkers in lung cancer . Cancer Lett.342 ( 2 ), 200 – 212 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ding L , ZhangZ , LiangGet al. Saha triggered met activation contributes to SAHA tolerance in solid cancer cells . Cancer Lett.356 ( 2 Pt B ), 828 – 836 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Imre G , GekelerV , LejaA , BeckersT , BoehmM . Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation . Cancer Res.66 ( 10 ), 5409 – 5418 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• West AC , JohnstoneRW . New and emerging HDAC inhibitors for cancer treatment . J. Clin. Invest.124 ( 1 ), 30 – 39 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Gryder BE , SodjiQH , OyelereAK . Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed . Future Med. Chem.4 ( 4 ), 505 – 524 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yardley DA , Ismail-KhanRR , MelicharBet al. Randomized Phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor . J. Clin. Oncol.31 ( 17 ), 2128 – 2135 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database: NCT01023308 . https://clinicaltrials.gov/ct2/show/NCT01023308 .
   Google Scholar
• San-Miguel JF , HungriaVT , YoonSSet al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind Phase III trial . Lancet Oncol.15 ( 11 ), 1195 – 1206 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M , SiegelDS , LonialSet al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (vantage 088): a multicentre, randomised, double-blind study . Lancet Oncol.14 ( 11 ), 1129 – 1140 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , MaitlandML , FrankelPet al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer . J. Clin. Oncol.28 ( 1 ), 56 – 62 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sandler A , GrayR , PerryMCet al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer . N. Engl. J. Med.355 ( 24 ), 2542 – 2550 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Laurie SA , SolomonBJ , SeymourLet al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC clinical trials group study BR29 . Eur. J. Cancer50 ( 4 ), 706 – 712 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG , BiesmaB , HeigenerDet al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer . J. Clin. Oncol.30 ( 25 ), 3084 – 3092 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Scagliotti G , NovelloS , Von PawelJet al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer . J. Clin. Oncol.28 ( 11 ), 1835 – 1842 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• De Boer RH , ArrietaO , YangCHet al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial . J. Clin. Oncol.29 ( 8 ), 1067 – 1074 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Herbst RS , SunY , EberhardtWEet al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (zodiac): a double-blind, randomised, Phase III trial . Lancet Oncol.11 ( 7 ), 619 – 626 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV , VynnychenkoI , ParkKet al. International, randomized, placebo-controlled, double-blind Phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1 . J. Clin. Oncol.30 ( 23 ), 2829 – 2836 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kubota K , IchinoseY , ScagliottiGet al. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (nsclc): Asian subgroup analysis . Ann. Oncol.25 ( 2 ), 529 – 536 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database: NCT00805194 . https://clinicaltrials.gov/ct2/show/NCT00805194 .
   Google Scholar
• Reck M , KaiserR , MellemgaardAet al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a Phase III, double-blind, randomised controlled trial . Lancet Oncol.15 ( 2 ), 143 – 155 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Herve V , RabbeN , GuilleminaultLet al. Vegf neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-RAS activating-mutations . MAbs6 ( 6 ), 1638 – 1648 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sims RJ , 3rd , ReinbergD . Is there a code embedded in proteins that is based on post-translational modifications?Nat. Rev. Mol. Cell Biol.9 ( 10 ), 815 – 820 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hartsough EJ , MeyerRD , ChitaliaVet al. Lysine methylation promotes vegfr-2 activation and angiogenesis . Sci. Signal.6 ( 304 ), ra104 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Rahimi N , CostelloCE . Emerging roles of post-translational modifications in signal transduction and angiogenesis . Proteomics15 ( 2–3 ), 300 – 309 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zecchin A , PattariniL , GutierrezMIet al. Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity . J. Mol. Cell Biol.6 ( 2 ), 116 – 127 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Marouco D , GarabadgiuAV , MelinoG , BarlevNA . Lysine-specific modifications of p53: a matter of life and death?Oncotarget4 ( 10 ), 1556 – 1571 ( 2013 ).
   PubMedGoogle Scholar
• Incani F , SerraM , MeloniAet al. Aire acetylation and deacetylation: effect on protein stability and transactivation activity . J. Biomed. Sci.21 , 85 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Liu W , FanLX , ZhouX , SweeneyWEJr , AvnerED , LiX . HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells . PLoS ONE7 ( 11 ), e49418 ( 2012 ).
   PubMed Web of Science ®Google Scholar